PepGen (PEPG) Other Non-Current Assets (2021 - 2026)
PepGen (PEPG) posted Other Non-Current Assets of $389000.0 for Q1 2026, down 74.87% sequentially from $1.5 million in Q4 2025, and down 74.87% YoY from $1.5 million in Q1 2025.
Analysis
PepGen (PEPG) Other Non-Current Assets (2021 - 2026) Analysis & Trends
PepGen has reported Other Non-Current Assets for 6 years, with the latest figure at $389000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 74.87% year-over-year to $389000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $389000.0 (down 74.87% YoY) and the FY2025 annual result came in at $1.5 million, changed 0.0% from the prior year.
- Other Non-Current Assets slipped to $389000.0 in Q1 2026 per PEPG's latest filing, from $1.5 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $3.6 million in Q1 2022 and troughed at $372000.0 in Q3 2025.
- A 5-year average of $1.5 million and a median of $1.5 million in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets gained 15.55% in 2023, then slumped 75.97% in 2025.
- Over 5 years, Other Non-Current Assets stood at $1.5 million in 2022, then grew by 5.09% to $1.5 million in 2023, then changed by 0.0% to $1.5 million in 2024, then changed by 0.0% to $1.5 million in 2025, then tumbled by 74.87% to $389000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $389000.0, $1.5 million, and $372000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - | 1.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.55 Mn |
| Mar 31, 2026 | 1.55 Mn |
| Dec 31, 2025 | 1.55 Mn |
| Sep 30, 2025 | 1.55 Mn |
| Jun 30, 2025 | 1.55 Mn |
| Mar 31, 2025 | 1.55 Mn |
| Dec 31, 2024 | 1.55 Mn |
| Sep 30, 2024 | 1.55 Mn |
| Jun 30, 2024 | 1.55 Mn |
| Mar 31, 2024 | 1.55 Mn |
| Dec 31, 2023 | 1.55 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Jun 30, 2023 | 1.70 Mn |
| Mar 31, 2023 | 1.47 Mn |
| Dec 31, 2022 | 1.47 Mn |
| Sep 30, 2022 | 1.47 Mn |
| Jun 30, 2022 | 1.47 Mn |
| Mar 31, 2022 | 3.64 Mn |
| Dec 31, 2021 | 3.02 Mn |